Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Fairlie

Showing results (1-10 of 326) with videos related to

Pageof 33
Sort By:
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 23, 2006
Protease inhibitors in the clinicGiovanni Abbenante, David P Fairlie
Current Medicinal Chemistry|December 28, 2005
Nonpeptide ligands that target peptide-activated GPCRs in inflammationJade S Blakeney, David P Fairlie
Drug Discovery Today|August 21, 2007
A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP bindingMarie A Bogoyevitch, David P Fairlie
Mini Reviews in Medicinal Chemistry|October 9, 2002
Mimetics of the peptide beta-strandMatthew P Glenn, David P Fairlie
Current Medicinal Chemistry|December 28, 2005
Therapeutic targets in inflammatory diseaseDavid A Hume, David P Fairlie
Immunology and Cell Biology|November 16, 2011
Lysine acetylation in obesity, diabetes and metabolic diseaseAbishek Iyer, David P Fairlie, Lindsay Brown
Biopolymers|May 15, 2016
Review stapling peptides using cysteine crosslinkingDavid P Fairlie, Aline Dantas de Araujo
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2025
Protease-activated receptor 2: A promising therapeutic target for women's cancersHimani Shah, David P Fairlie, Junxian Lim
Inorganic Chemistry|March 12, 1997
Oxygen versus Nitrogen Bonding of Carboxamides to Pentaammineruthenium(II/III)David P. Fairlie, Yigal Ilan, Henry Taube
The Journal of Pharmacology and Experimental Therapeutics|May 8, 2024
Protease-activated receptor 2: a promising therapeutic target for women's cancersHimani Shah, David P Fairlie, Junxian Lim
Pageof 33

Showing results (1-10 of 326) with videos related to

Sort By:
Pageof 33
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 23, 2006
Protease inhibitors in the clinicGiovanni Abbenante, David P Fairlie
Current Medicinal Chemistry|December 28, 2005
Nonpeptide ligands that target peptide-activated GPCRs in inflammationJade S Blakeney, David P Fairlie
Drug Discovery Today|August 21, 2007
A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP bindingMarie A Bogoyevitch, David P Fairlie
Mini Reviews in Medicinal Chemistry|October 9, 2002
Mimetics of the peptide beta-strandMatthew P Glenn, David P Fairlie
Current Medicinal Chemistry|December 28, 2005
Therapeutic targets in inflammatory diseaseDavid A Hume, David P Fairlie
Immunology and Cell Biology|November 16, 2011
Lysine acetylation in obesity, diabetes and metabolic diseaseAbishek Iyer, David P Fairlie, Lindsay Brown
Biopolymers|May 15, 2016
Review stapling peptides using cysteine crosslinkingDavid P Fairlie, Aline Dantas de Araujo
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2025
Protease-activated receptor 2: A promising therapeutic target for women's cancersHimani Shah, David P Fairlie, Junxian Lim
Inorganic Chemistry|March 12, 1997
Oxygen versus Nitrogen Bonding of Carboxamides to Pentaammineruthenium(II/III)David P. Fairlie, Yigal Ilan, Henry Taube
The Journal of Pharmacology and Experimental Therapeutics|May 8, 2024
Protease-activated receptor 2: a promising therapeutic target for women's cancersHimani Shah, David P Fairlie, Junxian Lim
Pageof 33